These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30010913)

  • 1. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.
    Feiring B; Laake I; Christiansen IK; Hansen M; Stålcrantz J; Ambur OH; Magnus P; Jonassen CM; Trogstad L
    J Infect Dis; 2018 Nov; 218(12):1900-1910. PubMed ID: 30010913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
    Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
    PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts.
    Molden T; Feiring B; Ambur OH; Christiansen IK; Hansen M; Laake I; Meisal R; Myrvang E; Jonassen CM; Trogstad L
    Papillomavirus Res; 2016 Dec; 2():153-158. PubMed ID: 29074174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.
    Laake I; Feiring B; Jonassen CM; Pettersson JHO; Frengen TG; Kirkeleite IØ; Trogstad L
    J Infect Dis; 2022 Sep; 226(4):625-633. PubMed ID: 33205203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
    Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
    Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
    Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
    JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
    Guo F; Hirth JM; Berenson AB
    Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
    Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
    J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
    Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
    Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
    Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
    Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
    Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
    J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
    Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.
    Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Lehtinen T; Natunen K; Damaso S; Soila M; Bi D; Struyf F
    Int J Cancer; 2020 Jul; 147(1):170-174. PubMed ID: 31736068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.